

Scheme 1. Reagents and conditions: (a) (i) pivaloyl chloride, DMSO, Et₃N, -78 °C; (ii) vinyl bromide, Mg, -78 °C, 2 h, 88%; (b) (-)-DIPT, Ti(O-ⁱPr)₄, TBHP, dry DCM, molecular sieves, 3 Å, -20 °C, 4 days, 49% for **5** and 46% for **6**; (c) TBS-OTf, 2,6-lutidine, dry CH₂Cl₂, 15 min, -10 °C, 90%; (d) (CH₃)₃S⁺I⁻, *n*-BuLi, -20 °C, 75% (e) Cl₃CNCO, K₂CO₃, CH₂Cl₂:CH₃OH (1.5:1), 4 h, 90%; (f) NaOH, *t*-BuOCl, ⁱPr₂EtN, potassium osmate, 2.5 h, 66%; (g) TsOH (Cat.), MeOH (h) (i) K₂CO₃, methanol, rt, 6 h; (ii) Ac₂O, pyridine, DMAP (cat), overnight, 82%.

chloride¹⁷ to give the aldehyde, which on Grignard reaction with vinyl magnesium bromide furnished the allylic alcohol **4** in 88% yield. The treatment of **4** with titanium tetraisopropoxide and *tert*-butylhydroperoxide in the presence of (-)-DIPT under Sharpless asymmetric kinetic resolution conditions¹⁸ provided the epoxy alcohol **5** and chiral allylic alcohol **6**¹⁹ in 46% yield and 97% ee (determined from the corresponding Mosher's ester). The epoxide **5** was found to be a mixture of *erythro* and *threo* (96:4) which was subsequently converted into their silyl derivatives by treatment with TBSOTf in the presence 2,6-lutidine. The required *erythro* isomer **7**²⁰ could easily be separated by column chromatography in 90% yield. Epoxide **7** was treated with excess of dimethylsulfonium methylide²¹ (generated from trimethylsulfonium iodide and *n*-BuLi) to furnish the allylic alcohol **8** in 75% yield. Alcohol **8** was then reacted with trichloroacetyl isocyanate in CH₂Cl₂ to give the corresponding isocyanate which on treatment with aq. K₂CO₃ and methanol furnished the carbamate **9** in 90% yield. The carbamate was converted into the oxazolidinone derivative **10** by a tethered aminohydroxylation protocol¹³ using *tert*-butyl hypochlorite as the oxidant, potassium osmate, NaOH, diisopropylethylamine, and propanol as the solvent. The reaction proceeded smoothly to furnish the protected aminoalcohol **10**²² in 66% yield with complete regio- and excellent diastere-

oselectivity (*syn:anti* 12:1, determined from ¹H NMR). The diastereomeric mixture could easily be separated by column chromatography. The key step in the tethered aminohydroxylation as depicted in Figure 2 is the intramolecular addition of the RN=Os=O fragment across the alkene leading to *syn* or *anti* relative stereochemistry.¹³ In the conformation **A**, due to the presence of hydrogen in the inside allylic position, the intramolecular approach of active osmium species to alkene would be favored thus leading to the major *syn*-product. The presence of bulky group (R in **B**) may hinder the approach of the active osmium species to the alkene and thus the reaction via conformation **B** leading to the *anti*-product is disfavored.

The compound **10** was desilylated using *p*-TSA and methanol to give the alcohol **11** in 78% yield, which on hydrolysis with K₂CO₃ in methanol furnished the crude aminoalcohol. Subsequent acylation using Ac₂O in the presence of pyridine and catalytic amount of DMAP produced the tetraacetate derivative of phytosphingosine **12**²³ in 82% yield.

For the synthesis of *L*-xylo-[2R,3S,4S]-C₁₈-phytosphingosine, the allylic alcohol **6** obtained by the chiral resolution of **4** was subjected to Sharpless asymmetric epoxidation to give the epoxide **13** in 75% yield as a single diastereomer, which was converted into the tetraacetate derivative of *L*-xylo-[2R,3S,4S]-C₁₈-phytosphingo-




Figure 2. Proposed transition states for the syn/anti selectivity observed during the TA reaction.

sine **14** following the same sequence of reactions as described for **12** (Scheme 1). The physical and spectroscopic data of **14** were in accordance with those described in literature.^{12b}

In conclusion, we have achieved a concise synthesis of both *l*-arabino- and *l*-xylo-phytosphingosines using tethered aminohydroxylation and Sharpless kinetic resolution as the key steps and as a source of chirality. The tethered aminohydroxylation was used to introduce the amino functionality in a highly diastereoselective manner. The generality of the method shown has significant potential of its further extension to the other isomers of phytosphingosine and related analogues. Currently studies are in progress to this direction.

Acknowledgments

A.D. thanks CSIR, New Delhi for the award of Senior Research Fellowship. Financial support for funding of the project (Grant No. SR/S1/OC-40/2003) from Department of Science & Technology, New Delhi is gratefully acknowledged. This is NCL Communication No. 6712.

References and notes

- (a) Hannun, Y. A. *Sphingolipid-Mediated Signal Transduction*; R.G. Landes Company: Austin, 1997; (b) Merrill, A. H.; Sweeley, C. C. In *Biochemistry of Lipids, Lipoproteins and Membranes*; Vance, D. E., Vance, J., Eds.; Elsevier: Amsterdam, 1996; Vol. 31, p 309; (c) Abbas, H. K.; Tanaka, T.; Duke, S. D.; Porter, J. K.; Wray, E. M.; Hodges, L.; Session, A. E.; Wang, E.; Messill, A. H., Jr.; Riley, R. J. *Plant Physiol.* **1994**, *106*, 1085; (d) Porcelli, S. A.; Moddlin, R. L. *Annu. Rev. Immunol.* **1999**, *17*, 297; (e) Hanum, Y. A. *Science* **1996**, *274*, 1855; (f) Ariga, T.; Jaruis, W. D.; Yu, R. K. *J. Lipid Res.* **1998**, *39*, 1; (g) Perry, D. K.; Hannun, Y. A. *Biochim. Biophys. Acta* **1998**, *1436*, 233.
- Hannun, Y. A.; Bell, R. M. *Science* **1989**, *243*, 500.
- Okabe, K.; Keeman, R. W.; Schmidt, G. *Biochem. Biophys. Res. Commun.* **1968**, *31*, 137.
- Takamastu, K.; Mikami, M.; Kikuchi, K.; Nozawa, S.; Iwamori, M. *Biochim. Biophys. Acta* **1992**, *1165*, 177.
- Barenholz, Y.; Gatt, S. *Biochem. Biophys. Res. Commun.* **1967**, *27*, 319.
- (a) Wertz, P. W.; Miethke, M. C.; Long, S. A.; Stauss, J. S.; Dowling, D. T. *J. Invest. Dermatol.* **1985**, *84*, 410; (b) Schmidt, R. R. In *Liposome Dermatics*; Braun-Falco, O., Corting, H. C., Maibach, H. I., Eds.; Springer: Berlin, 1992; p 44.
- (a) Karlsson, K. A.; Samuelsson, B. E.; Steen, G. O. *Acta Chem. Scand.* **1968**, *22*, 136; (b) Karlsson, K. A. *Acta Chem. Scand.* **1964**, *18*, 2395.
- Vance, D. E.; Sweeley, C. C. *J. Lipid Res.* **1967**, *8*, 621.
- Zellen, J. *Monatsh. Chem.* **1911**, *32*, 133.
- (a) Oda, T. *J. Pharma. Soc. Jpn.* **1952**, *72*, 142; (b) Carter, H. E.; Hendrickson, H. S. *Biochemistry* **1963**, *2*, 389.
- (a) Dikson, R. C.; Nagiec, E. E.; Skrzypek, M.; Tillman, P.; Wells, G. B.; Lester, R. L. *J. Bol. Chem.* **1997**, *272*, 30196; (b) Schniter, R. *BioEssays* **1999**, *21*, 1004; (c) Kobayashi, E.; Motoski, K.; Yamaguchi, Y.; Uchida, T.; Fukushima, H.; Koezuka, Y. *Oncol. Res.* **1995**, *7*, 529.
- (a) Fernandes, R. A.; Kumar, P. *Tetrahedron Lett.* **2000**, *41*, 10309; (b) Fernandes, R. A.; Kumar, P. *Synthesis* **2003**, *1*, 129; (c) Kumar, P.; Naidu, S. V. *Tetrahedron Lett.* **2003**, *44*, 1035; (d) Azuma, H.; Tamagaki, S.; Ogino, K. *J. Org. Chem.* **2000**, *65*, 3538; (e) Abraham, E.; Brock, E. A.; Candela-Lena, J. I.; Davis, S. G.; Georgiou, M.; Nicholson, R. L.; Perkins, J. H.; Roberts, P. M.; Russell, A. J.; Sanchez-Fernandez, E. M.; Scott, A. D.; Thomson, J. E. *Org. Biomol. Chem.* **2008**, *6*, 1665. and references cited therein.
- (a) Donohoe, T. J.; Johnson, P. D.; Helliwell, M.; Keenan, M. *Chem. Commun.* **2001**, *3*, 401; (b) Donohoe, T. J.; Johnson, P. D.; Cowley, A.; Keenan, M. *J. Am. Chem. Soc.* **2002**, *124*, 12934; (c) Donohoe, T. J.; Johnson, P. D.; Pye, R. J. *Org. Biomol. Chem.* **2003**, *1*, 2025; (d) Donohoe, T. J.; Johnson, P. D.; Pye, R. J.; Keenan, M. *Org. Lett.* **2004**, *6*, 2583; (e) Donohoe, T. J.; Carole, J. R.; William, G.; Johannes, K.; Emile, R. *Org. Lett.* **2007**, *7*, 1725.
- (a) Li, G.; Chang, H. T.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **1996**, *35*, 451; (b) Brien, P. O. *Angew. Chem., Int. Ed.* **1999**, *38*, 326. and references cited therein.
- (a) Kandula, S. V.; Kumar, P. *Tetrahedron Lett.* **2003**, *44*, 6149; (b) Kumar, P.; Naidu, S. V.; Gupta, P. *J. Org. Chem.* **2005**, *70*, 2843; (c) Kumar, P.; Naidu, S. V. *J. Org. Chem.* **2005**, *70*, 4207; (d) Kumar, P.; Naidu, S. V. *J. Org. Chem.* **2006**, *71*, 3935; (e) Kumar, P.; Gupta, P.; Naidu, S. V. *Chem. Eur. J.* **2006**, *12*, 1397; (f) Gupta, P.; Kumar, P. *Eur. J. Org. Chem.* **2008**, 1195. and references cited therein.
- (a) Fernandes, R. A.; Kumar, P. *Eur. J. Org. Chem.* **2000**, 3447; (b) Kandula, S. V.; Kumar, P. *Tetrahedron Lett.* **2003**, *44*, 1957; (c) Kondekar, N. B.; Subba Rao, K. V.; Kumar, P. *Tetrahedron Lett.* **2004**, *45*, 5477; (d) Kumar, P.; Bodas, M. S. *J. Org. Chem.* **2005**, *70*, 360; (e) Pandey, S. K.; Pandey, M.; Kumar, P. *Tetrahedron Lett.* **2008**, *49*, 2397. and references cited therein.
- Dubey, A.; Kandula, S. R. V.; Kumar, P. *Synth. Commun.* **2008**, *38*, 746.
- Martin, V. S.; Woodard, S. S.; Katuski, T.; Yamada, Y.; Ikeda, M.; Sharpless, K. B. *J. Am. Chem. Soc.* **1981**, *103*, 6237.
- Spectral data of **6**: mp = 46 °C. $[\alpha]_D^{25} +2.38$ (c 1.0, CHCl₃); ¹H NMR (CDCl₃, 200 MHz): δ 0.89 (t, J = 6.1 Hz, 3H), 1.26 (m, 24H), 1.54 (m, 2H), 1.69 (br s, 1H), 4.11 (m, 1H), 5.08–5.26 (m, 2H), 5.78–5.95 (m, 1H); ¹³C NMR (CDCl₃, 50 MHz): δ 14.0, 22.6, 25.3, 25.7, 29.3, 29.6, 31.8, 32.6, 36.9, 62.6, 73.0, 114.2, 141.3; Anal. Calcd for C₁₇H₃₄O (254.45): C, 80.24; H, 13.47. Found: C, 79.95; H, 13.73.
- Spectral data of **7**: $[\alpha]_D^{25} -4.1$ (c 1.0, CHCl₃); ¹H NMR (200 MHz, CDCl₃): δ 0.07 (s, 3H), 0.12 (s, 3H), 0.84–0.93 (m, 12H), 1.26 (s, 24 H), 1.49–1.53 (m, 2H), 2.55 (q, J = 2.72, 5.12, 1H), 2.75–2.83 (m, 1H), 2.87–2.97 (m, 1H), 3.19–3.33 (m, 1H); ¹³C NMR (50 MHz, CDCl₃): δ -4.9, -4.4, 14.0, 18.1, 22.6, 24.8, 25.2, 25.6, 25.7, 25.9, 29.3, 29.5, 29.6, 29.7, 31.9, 35.2, 44.7, 54.6, 71.2; Anal. Calcd for C₂₃H₄₆O₂Si (384.71): C, 71.81; H, 12.58. Found: C, 71.65; H, 12.73.
- Alcaraz, L.; Harnett, J. J.; Mioskowski, C.; Martel, J. P.; Le Gall, T.; Dong-Soo, Shin; Falck, J. R. *Tetrahedron Lett.* **1994**, *35*, 5449.
- Spectral data of **10**: $[\alpha]_D^{25} +28.47$ (c 1.3, CHCl₃); ¹H NMR (200 MHz, CDCl₃): δ 0.09 (s, 3H), 0.10 (s, 3H), 0.88–0.91 (m, 12H), 1.26 (m, 24 H), 1.39–1.41 (m, 2H), 3.42–3.6 (m, 1H), 3.65–3.8 (m, 1H), 3.85–4 (m, 2H), 4.32 (m, 1H), 6.55 (s, 1H); ¹³C NMR (50 MHz, CDCl₃): δ -4.6, -4.4, 14.0, 17.9, 22.6, 24.9, 25.7, 29.3, 29.6, 31.8, 32.8, 54.3, 63.8, 71.9, 80.3, 160.3; Anal. Calcd for C₂₅H₅₁NO₄Si (457.76): C, 65.59; H, 11.23; N, 3.06. Found: C, 65.35; H, 11.48; N, 3.36.
- Spectral data of **12**: mp = 48 °C; $[\alpha]_D^{20} -25.95$ (c 1.5, CHCl₃); lit. ^{12d} $[\alpha]_D^{20} -25.1$ (c 1.5, CHCl₃); ¹H NMR (200 MHz, CDCl₃): 0.86 (t, J = 6 Hz, 3H), 1.2–1.3 (m, 24 H), 1.55 (m, 2H), 2.03 (s, 3H), 2.04 (s, 6H), 2.07 (s, 3H), 3.95–4.05 (m, 2H), 4.5 (m, 1H), 5.02–5.18 (m, 2H), 5.92 (d, J = 10 Hz, 1H). ¹³C NMR (50 MHz, CDCl₃): δ 14.6, 21.2, 21.4, 23.6, 25.5, 30.1, 32.4, 33.9, 47.5, 63.5, 71.4, 72.4, 170.3, 170.6, 170.7, 171.1.